Baldessarini R.J. (1996) Drugs and the treatment of psychiatric disorders . In Hardmann JG, Limbird LE, Molinoff PB, Ruddon R W, Goodman Gilman A (eds), Goodman & Gilman's the pharmacological basis of therapeutics. McGraw Hill, New York
2.
Harvey AT, Preskorn SH (1996) Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors.Part I. J Clin Psychopharmac16: 273-285
3.
Ketter TA, Flockhart DA, Post RM, Denicoff K., Pazzaglia PJ, Marangell L.B., George M.S., Callahan AM (1995) The emerging role of cytochrome P450 3A in psychopharmacology . J Clin Psychopharmac15: 387-398
4.
Malik K. (1996) Nefazodone: structure, mode of action and pharmacokinetics . J Psychopharmac10 (Suppl. 1): 1-4
5.
Marcus R.N. (1996) Safety and tolerability profile of nefazodone. J Psychopharmac10 (Suppl. 1): 11-17
6.
McNamara JO (1996) Drugs effective in the treatment of the epilepsies . In Hardman JG, Limbird L E, Molinoff P B, Ruddon R W, Goodman Gilman A (eds), Goodman & Gilman's the pharmacological basis of therapeutics. McGraw Hill, New York
7.
Nemeroff CB, Lindsay DeVane C., Pollock BC (1996) Newer antidepressants and the cytochrome P450 system . Am J Psychiat153: 311-320
8.
Preskorn S.H. (1993) Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiat54 (Suppl. 9): 14-34
9.
Preskorn S.H. (1995) What is the message in the alphabet soup of cytochrome P450 enzymes? J Pract Psychiat Behav Hlth1: 237-240
10.
Richelson E. (1994) The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiat55 (Suppl. A): 34-39
11.
Sternbach H. (1991) The serotonin syndrome. AmJ Psychiat148 : 705-713
